Anti-Xa AC Reversal: Phase III Results

Anti-Xa AC Reversal: Phase III Results
Jan 10, 2015 7:53am

On January 9, 2014, Portola Pharmaceuticals announced the results of their phase III trial of intravenous Andexanet Alfa, an anti-Xa reversal agent. The trial, ANNEXA-R, tested Andexanet against rivaroxaban, however subsequent trials will generalize it to the additional anti-Xa 's apixaban and edoxaban. Dave McGlasson comments and a January 9 article appears in The Heart, which mentions that Boehringer Ingelheim is also working on a reversal agent for dabigatran.

1 Comment
By Clinical Research Scientist David McGlasson
Jan 12, 2015 4:18pm
Today in the money section of CNN, Porta Pharmaceuticals announced the initiation of a phase IV study to support accelerated approval of Andexanet Alfa anti-Xa reversal agent. I find it interesting that this comes almost one year after their releasing of their phase III study. Looks like they may have a winner to reverse the effects of a bleed caused by the anti-Xa TSOAC inhibitors.

Leave A Comment

You must be logged in to Comment - Sign In